Scoring index for prediction of HER-2 status in the invasive breast carcinoma

Experimental Oncology

Volumn 29, Issue 4, 2007, Pages 281-286

  Kajo, K ^a   Zubor, P ^a   Barthova, M ^a   Plank, L ^a  

^a Jessenius Faculty of Medicine in Martin and University Hospital Martin   (Slovakia)

Author keywords

Breast carcinoma; CISH; HER 2; Immunohistochemistry; Scoring index

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROGESTERONE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CONTROLLED STUDY; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESEARCH DESIGN;

EID: 39049118309     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989; 4: 362-6.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
4. Ross JS, Fletcher JA. Her (c-erb-B2) gene and protein in breast cancer. A Pathol 1999; 112: 523-67.
5. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24: 85-95.
6. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-25.
7. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficiacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001; 344: 783-92.
9. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
10. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005; 123: 541-6.
11. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001; 10: 139-52.
12. Bianco AR, De Laurentiis M, Carlomagno C, et al. HER2 overexpression predict adjuvant tamoxifen (TAM) failure for erderly breast cancer (EBC): complete data at 20 yr of the Naples GUN randomised trial. Proc Am Soc Clin Oncol 2000; 19: 75.
13. Lipton A, Ali SM, Leitzel K, et al. Elevated serum HER-2/neu level predict decreseased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20: 1467-72.
14. Yaziji H, Goldstein LC, Barry TS, et al. HER2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972-7.
15. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467-72.
16. Bilous M, Morey A, Armes JE, et al. CISH or FISH? The interlaboratory reproducibility of CISH testing for HER2 and correlation with IHC and FISH results. Eur J Cancer Suppl 2004; 2: 100.
17. Peiro G, Mayr D, Hillemanns P, et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridisation. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki67 protein expression, and outcome. Mod Pathol 2004; 17: 227-87.
18. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 2005; 18: 1015-21.
19. Taucher S, Rudas M, Mader RM, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 2003; 98: 2547-53.
20. Bilous M, Ades C, Armes J, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. The Breast 2003; 12: 92-8.
21. Huang HJ, Neven P, Drijkoningen M, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005; 16: 1755-61.
22. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer, College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.
23. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. FA Tavassoli, P Devilee, eds. Lyon, France: IARC Press; 2003: 13-59.
24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
25. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004; 10: 4793-8.
26. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003; 16: 173-82.
27. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic singificance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49: 44-9.
28. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: A retrospective analysis of 176 cases. Cancer 1990; 65: 1794-800.
29. Hoff ER, Tubbs RR, Myles JL, et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 2002; 117: 916-21.
30. Kajo K, Zubor P, Plank L, et al. Score system evaluation of HER2 state possibility in breast cancer. 7th Milan Breast Cancer Conference. Book of abstracts, Milan, 2005: p 73.
31. Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003; 88: 1587-91.